As part of BIOAXXESS UK’s continued efforts to support the challenge to develop reliable SARS-CoV-2 (Covid-19) antibody tests, we are pleased to announce CANDOR Bioscience’s new PlateBlockTM blocking reagent that has shown superior surface blocking results for ELISA-based immunoassays for Covid-19 and other types of infectious disease diagnostics.
PlateBlockTM efficiently blocks unspecific binding of IgG antibodies in human serum samples to the ELISA plate.
How CANDOR Bioscience products can help the development of better Covid-19 antibody tests:
Use PlateBlockTM to minimise the number of false positive results for antigen-down ELISAs detecting high-affinity anti-SARS-CoV-2 IgG antibodies in patient blood samples diluted as low as 1:10 to allow for excellent sensitivity in serological tests.
Combine low background with superior specificity for SARS-CoV-2 by using CANDOR’s LowCross-Buffer® as anti-interference sample dilution buffer.
LowCross-Buffer® acts as an “affinity filter” that excludes assay signals due to low to medium affinity antibodies that may be already present against other related corona viruses from previous infections.
Instead, zoom in on human antibodies with high affinity to SARS-CoV-2 that are expected to confer Covid-19 immunity in asymptomatic individuals or those who experienced only mild Covid-19 symptoms.
The same approach is crucial for the assessment of immunity in healthy individuals currently taking part in clinical studies of experimental vaccine projects against SARS-CoV-2.
BIOAXXESS are pleased to offer CANDOR’s ELISA Sampler Package CoViD-19 as a tool box, which contains the novel PlateBlockTM together with the key CANDOR reagents required for professional ELISA development and manufacturing.
CANDOR Bioscience just published two White Papers on how their products, including the new PlateBlockTM can help to design, develop and manufacturer high quality Covid-19 antibody tests for routine laboratory use (in vitro diagnostic assays, ELISA):
See Fig. 4 on PlateBlockTMcompared to other ELISA plate blockers as taken from CANDOR’s White Paper ‘Covid-19 Antibody Test Challenge’.